主动脉内脏分支血管干预对B型主动脉夹层合并内脏灌注不良TEVAR术后结局的影响
基于血管外科学会血管质量倡议数据库的多机构真实世界研究,纳入477例因B型主动脉夹层合并内脏灌注不良行TEVAR的患者,比较联合内脏分支血管干预与不联合干预的术后结局。联合干预组30天全因死亡率、灌注不良相关死亡率及主要不良心血管事件调整后 odds 均显著降低,但内脏分支再干预 odds 增高。作者据此建议对灌注不良患者降低内脏分支血管干预的门槛,并需进一步前瞻性研究确认。
要点
- TEVAR联合内脏分支血管干预组30天全因死亡率9.8%,低于未联合干预组的17.3%(P = .032)。
- 调整混杂后联合干预组30天死亡 odds 降低90%(OR 0.10;95%CI 0.03-0.40;P = .001)。
- 联合干预组内脏分支再干预率11.8%,高于未联合干预组的6.2%(P = .035)。
核心结论
- 在B型主动脉夹层合并内脏灌注不良患者中,TEVAR联合内脏分支血管干预与30天死亡率、灌注不良相关死亡率及主要不良心血管事件 odds 显著降低相关,但与内脏分支再干预 odds 增高相关。
- 作者建议对灌注不良患者降低实施内脏分支血管干预的门槛,并指出需进一步前瞻性研究确认这些发现并识别最可能获益的患者。
研究设计与样本
- 研究基于血管外科学会血管质量倡议数据库,纳入因B型主动脉夹层合并肝、肠或肾灌注不良行TEVAR的患者。
- 最终分析纳入477例患者,按主要暴露变量分为TEVAR联合辅助性内脏分支血管干预组153例(32.1%)与不联合干预组324例(67.9%)。
- 联合干预指对腹腔干、肠系膜上动脉、右肾动脉或左肾动脉中至少一支存在灌注不良的血管行辅助性干预。
- 比较两组基线人口学、临床及围术期特征,以及30天全因死亡率、灌注不良相关死亡率、主要不良心血管事件、总体并发症、再干预及内脏分支再干预等结局,并行单变量和多变量分析。
主要发现
- 联合干预组30天全因死亡率为9.8%,不联合干预组为17.3%(P = .032)。
- 联合干预组灌注不良相关死亡率为3.3%,不联合干预组为9.6%(P = .015)。
- 联合干预组主要不良心血管事件发生率为15.7%,不联合干预组为22.8%,差异未达统计学显著(P = .071)。
- 联合干预组内脏分支再干预率为11.8%,不联合干预组为6.2%(P = .035)。
- 调整潜在混杂因素后,联合干预组30天死亡 odds 降低90%(OR 0.10;95%CI 0.03-0.40;P = .001),灌注不良相关死亡 odds 降低78%(OR 0.22;95%CI 0.05-0.95;P = .043),主要不良心血管事件 odds 降低50%(OR 0.50;95%CI 0.25-0.97;P = .040),内脏分支再干预 odds 增高(OR 2.36;95%CI 1.01-5.52;P = .047)。
临床怎么用
- 作者基于这些结果建议对灌注不良患者降低实施内脏分支血管干预的门槛。
- 作者指出需进一步前瞻性研究确认这些发现并识别最可能从内脏分支血管干预中获益的患者。
局限性
- 原文结论指出需进一步前瞻性研究确认这些发现并识别最可能从内脏分支血管干预中获益的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thoracic endovascular aortic repair (TEVAR) is the standard of care for type B aortic dissection (TBAD) complicated with visceral malperfusion. TEVAR is considered efficient at relieving malperfusion caused by dynamic obstruction but not static obstruction, and as such, some patients also require adjunctive visceral branch vessel interventions (VBIs). The role of VBIs in patients undergoing TEVAR for TBAD complicated with visceral malperfusion is a subject of considerable debate. This study aimed to compare the postoperative outcomes of TEVAR with VBI vs without for TBAD complicated with visceral malperfusion in a real-world multi-institutional setting. METHODS: The Society for Vascular Surgery Vascular Quality Initiative database was queried for patients who underwent TEVAR for TBAD complicated with hepatic, intestinal, or renal malperfusion. The cohort was divided into two groups based on the main exposure variable: TEVAR with adjunctive VBI vs without on either celiac artery, superior mesenteric artery, right renal artery, or left renal artery, presenting with malperfusion. Baseline demographic, clinical, and perioperative characteristics, as well as outcomes such as overall 30-day mortality, malperfusion-related mortality, major adverse cardiovascular events (MACEs: death, myocardial infarction, or stroke), overall complications, reinterventions, and visceral branch reinterventions, were compared between the groups. Univariable and multivariable analyses were performed. RESULTS: Of all reviewed patients, 477 were involved in the final analysis, 324 (67.9%) underwent TEVAR without a VBI, whereas 153 (32.1%) underwent TEVAR in association with an adjunctive intervention on at least one of the visceral branches (celiac artery, superior mesenteric artery, right renal artery, left renal artery), presenting with malperfusion. Patients who underwent TEVAR with a VBI had significantly lower rates of overall 30-day mortality (9.8% vs 17.3%; P = .032), malperfusion-related mortality (3.3% vs 9.6%; P = .015), a tendency toward a lower rate of MACE (15.7% vs 22.8%; P = .071), and a higher rate of visceral branch reinterventions (11.8% vs 6.2%; P = .035). After adjustment for potential confounders, patients who underwent TEVAR with a VBI had 90% decreased odds of 30-day mortality (odds ratio [OR], 0.10; 95% confidence interval [CI], 0.03-0.40; P = .001), 78% decreased odds of malperfusion-related mortality (OR, 0.22; 95% CI, 0.05-0.95; P = .043), 50% decreased odds of MACE (OR, 0.50; 95% CI, 0.25-0.97; P = .040), and increased odds of visceral branch reinterventions (OR, 2.36; 95% CI, 1.01-5.52; P = .047). CONCLUSIONS: TEVAR with VBI is associated with significantly reduced odds of 30-day mortality, malperfusion-related mortality, and MACE, but increased odds of visceral branch reinterventions in TBAD patients presenting with visceral malperfusion. Based on these results, a lower threshold for performing VBI is recommended for patients with malperfusion. Further prospective studies are required to confirm these findings and to identify patients who would benefit from VBI the most.
引用
- Veranyan N, Kang Sim DE, Magee GA, et al. Impact of aortic visceral branch vessel interventions on the postoperative outcomes of thoracic endovascular aortic repair for type B aortic dissection complicated with visceral malperfusion. J Vasc Surg. 2025. PMID: 40348289. doi:10.1016/j.jvs.2025.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。